Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
5,32 USD | +1,92% | -3,10% | -47,48% |
13/03 | Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM | |
29/02 | EDITAS MEDICINE, INC. : per Barclays il titolo è Neutral | ZM |
Attività
Numero di dipendenti: 265
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Genome Editing Technology
100,0
%
| 20 | 100,0 % | 78 | 100,0 % | +296,32% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 20 | 100,0 % | 78 | 100,0 % | +296,32% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Gilmore O’Neill
CEO | Chief Executive Officer | 59 | 01/06/22 |
Erick Lucera
DFI | Director of Finance/CFO | 57 | 17/05/23 |
Linda Burkly
CTO | Chief Tech/Sci/R&D Officer | - | 24/07/23 |
Mei Baisong
CTO | Chief Tech/Sci/R&D Officer | 60 | 18/07/22 |
Chi Li
LAW | General Counsel | - | 14/06/21 |
Linea Aspesi
HRO | Human Resources Officer | - | 01/02/23 |
Charlene Stern
LAW | General Counsel | - | 01/01/13 |
Kate X. Zhang
PRN | Corporate Officer/Principal | - | 01/10/18 |
Caren Deardorf
PRN | Corporate Officer/Principal | 59 | 26/09/23 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Emma Reeve
CHM | Chairman | 63 | 03/09/21 |
David Scadden
BRD | Director/Board Member | 71 | 06/02/19 |
Akshay Vaishnaw
BRD | Director/Board Member | 61 | 28/07/16 |
Andrew Hirsch
BRD | Director/Board Member | 53 | 30/05/17 |
Jessica Hopfield
BRD | Director/Board Member | 59 | 16/02/18 |
Elliott Levy
BRD | Director/Board Member | 64 | 11/04/23 |
Director/Board Member | 65 | 26/10/21 | |
Gilmore O’Neill
CEO | Chief Executive Officer | 59 | 01/06/22 |
Meeta Chatterjee
BRD | Director/Board Member | 69 | 17/12/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 82 234 710 | 81 969 942 ( 99,68 %) | 0 | 99,68 % |
Coordinate società
Settore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-47,48% | 437 Mln | |
+1,51% | 42,75 Mrd | |
+49,22% | 41,61 Mrd | |
+8,57% | 41,34 Mrd | |
-12,36% | 26,59 Mrd | |
+8,92% | 25,49 Mrd | |
-25,13% | 18,12 Mrd | |
+29,17% | 12,24 Mrd | |
-3,12% | 11,76 Mrd | |
+6,35% | 11 Mrd |
- Borsa valori
- Azioni
- Azione EDIT
- Società Editas Medicine, Inc.